Amdinocillin

This is the authors' abstract. We don't add key points for this paper.

Editorials1 September 1984AmdinocillinW. EDMUND FARRAR, M.D.W. EDMUND FARRAR, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-3-389 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTwelve years ago Lund and Tybring (1) described a new antibiotic, amdinocillin (mecillinam), an amidinopenicillin that differs significantly from conventional penicillins and cephalosporins in the nature of the bond between the side chain and the nitrogen attached at the 6-position of the beta-lactam ring (Figure 1). This agent is likely to be released for clinical use in the United States in the near future.From the clinician's point of view, the chief interest of amdinocillin lies in its high degree of activity against many species of enteric gram-negative bacilli, includingEscherichia coli, Salmonella, Shigella, Citrobacter, Enterobacter, Klebsiella, Proteus, andSerratia...References1. LUNDTYBRING FL. 6 β-aminidinopenicillanic acids—a new group of antibiotics. Nature New Biol. 1972;236:135-7. CrossrefMedlineGoogle Scholar2. MOELLERINGNELSONNEU RJH. An international review of amdinocillin: a new beta-lactam antibiotic. Am J Med. 1983;75(suppl, August 29):1-3. CrossrefGoogle Scholar3. REEVES D. Antibacterial activity of mecillinam. J Antimicrob Chemother. 1977;3(supl B):5-11. CrossrefMedlineGoogle Scholar4. SPRATT B. The mechanism of action of mecillinam. J Antimicrob Chemother. 1977;3(suppl B):13-9. CrossrefMedlineGoogle Scholar5. NEU H. Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death. Am J Med. 1983;75(suppl, August 29):9-20. CrossrefMedlineGoogle Scholar6. KRAMERMAURIZTIMMESROBERTSONCLEELAND MYMTR. Morphologic changes produced by amdinocillin alone and in combination with beta-lactam antibiotics: in vitro and in vivo. Am J Med. 1983;75(suppl, August 29):30-41. CrossrefMedlineGoogle Scholar7. ISHINOTAMAKISPRATTMATSUHASHI FSBM. A mecillinam-sensitive peptidoglycan crosslinking reaction to Escherichia coli. Biochem Biophys Res Commun. 1982;109:689-96. CrossrefMedlineGoogle Scholar8. CLEELANDSQUIRES RE. Enhanced activity of beta-lactam antibiotics with amdinocillin: in vitro and in vivo. Am J Med. 1983;75(suppl, August 29):21-9. CrossrefMedlineGoogle Scholar9. RICHMOND M. In vitro studies with mecillinam on Escherichia coli and Pseudomonas aeruginosa. J Antimicro Chemother. 1977;3(suppl B):29-39. CrossrefMedlineGoogle Scholar10. NEU H. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam. Antimicrob Agents Chemother. 1982;22:518-9. CrossrefMedlineGoogle Scholar11. TANSALSTROMFILE JST. Levels of amdinocillin in human plasma and interstitial fluid following intravenous administration. Am J Med. 1983;75(suppl, August 29):65-7 CrossrefMedlineGoogle Scholar12. GAMBERTOGLIOBARRIERELINCONTE JSEJ. Amdinocillin pharmacokinetics: simultaneous administration with cephalothin and cerebrospinal fluid penetration. Am J Med. 1983;75(suppl, August 29):54-9. CrossrefMedlineGoogle Scholar13. HARESHEGARTYTOMKYNSBURDONKEIGHLEY MAJDM. A study of the biliary excretion of mecillinam in patients with biliary disease. J Antimicrob Chemother. 1982;9:217-22. CrossrefMedlineGoogle Scholar14. MYERSJACOBSONMASCISRULEVITCHHIRSCHMAN BJJES. Pharmacokinetics of amdinocillin in healthy adults. Antimicrob Agents Chemother. 1983;23:827-30. CrossrefMedlineGoogle Scholar15. LAWSONESTEYBODEY REG. Amdinocillin: use alone or in combination with cefoxitin or carbenicillin-ticarcillin. Am J Med. 1983;75(suppl, August 29):113-8. CrossrefMedlineGoogle Scholar16. GEDDESCLARKE AP. The treatment of enteric fever with mecilinam. J Antimicrob Chemother. 1977;3(suppl B): 101-2. CrossrefMedlineGoogle Scholar17. LIMSONMENDOZALIWANAGCHRISTENSINMENDAY RMEOP. Randomised, comparative trial of mecillinam, mecillinam/ampicillin and chloramphenicol in the treatment of enteric fever. J Antimicrob Chemother. 1982;9:405-10. CrossrefMedlineGoogle Scholar18. BALLGEDDES AA. Management of enteric fever with amdinocillin. Am J Med. 1983;75(suppl, August 29):130-3. CrossrefMedlineGoogle Scholar19. JONSSON M. Pivmecillinam in the treatment of Salmonella carriers. J Antimicrob Chemother. 1977;3(suppl B): 103-7. CrossrefMedlineGoogle Scholar20. BLACKGAARSLEVORSKOV FKF. Mecillinam, a new prophylactic for travellers' diarrhoea: a prospective double-blind study in tourists travelling to Egypt and the Far East. Scand J Infect Dis. 1983;15:189-93. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Medical University of South Carolina Charleston, South Carolina PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByClinical isolates of Escherichia coli solely resistant to mecillinam: prevalence and epidemiologyEmerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteriaEffect of Perorally Administered Pivmecillinam on the Normal Oropharyngeal, Intestinal and Skin MicrofloraCommentary 1 September 1984Volume 101, Issue 3Page: 389-390KeywordsEnterobacterEscherichia coliForecastingKlebsiellaPenicillinSalmonellaShigella Issue Published: 1 September 1984 PDF DownloadLoading ...